INS and pancreatic insulinoma: While pasireotide has not demonstrated a definitive antiproliferative effect (29), its hyperglycemic effect, mediated through its particular affinity for somatostatin receptors 5 (SSTR5), which results in suppression of insulin secretion from pancreatic cells (11), proves therapeutically advantageous in insulinoma (11, 26, 30).